Important price reduction improves access to TB prevention

KNCV Tuberculosis Foundation welcomes the announcement of a substantial reduction in the price of an anti-tuberculosis medicine through the support of Unitaid and the Global Fund, in partnership with the manufacturer Sanofi-Pasteur.

The ant-tuberculosis drug Rifapentine (P) can be taken together with isoniazid (H) once a week for three months in a regimen known as ‘3HP’ to treat latent TB infection (LTBI). This WHO approved combination is shorter, easier to take and just as effective as standard daily treatments, but until now was much more costly. This price reduction is an important step, making the prevention of TB more affordable for public sector use in low- and middle-income countries with high burdens of TB and HIV.

Expanded access to safe, effective and affordable medicines is essential for millions of people at risk around the world to protect themselves against tuberculosis. TB is still the deadliest infectious disease in the world, killing over 4.000 people every day. Unnecessary, because with the right treatment TB can be cured and it can also be prevented. The immune system prevents this for most people; when someone is infected, LTBI can lay dormant for years. Without treatment 5 to 10 percent of infected people will at some point develop active TB and get ill. Vulnerable people, like young children and people living with HIV, have the highest risk to develop active TB.

Agnes Gebhard, director technical division of KNCV Tuberculosis Foundation: “KNCV is currently supporting countries in Africa and Asia to introduce 3HP treatment. We applaud the price reduction of rifapentine, which enables the countries to move ahead, being the first to roll-out large scale access to this innovative treatment for TB infection.”

One of the projects in which KNCV collaborates on 3HP introduction is the Aurum Institute-led and Unitaid-funded IMPAACT4TB project, KNCV being the project lead in Ethiopia, Tanzania, Malawi and Indonesia.

Read more:
The price reduction of rifapentine was announced today by Unitaid, the Global Fund to Fight Aids, Tuberculosis and Malaria and Sanofi. More information can be found here.

 

 

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Address

KNCV Tuberculosefonds
Maanweg 174
2516 AB Den Haag
+31 70 416 7222

OPEN IN GOOGLE MAPS

Postal address

Postbus 146
2501 CC Den Haag

More information

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.